vs
Side-by-side financial comparison of BEYOND MEAT, INC. (BYND) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
BEYOND MEAT, INC. is the larger business by last-quarter revenue ($61.6M vs $57.3M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -19.7%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -9.7%).
Beyond Meat, Inc., branded as Beyond, is a producer of plant-based meat alternatives founded in 2009 by Ethan Brown. The company's products were first launched in the United States in 2012.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
BYND vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $61.6M | $57.3M |
| Net Profit | — | $-47.5M |
| Gross Margin | -11.5% | 91.6% |
| Operating Margin | -211.4% | -82.2% |
| Net Margin | — | -83.0% |
| Revenue YoY | -19.7% | 36.9% |
| Net Profit YoY | — | -9.6% |
| EPS (diluted) | $0.68 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.6M | $57.3M | ||
| Q3 25 | $70.2M | $51.3M | ||
| Q2 25 | $75.0M | $48.5M | ||
| Q1 25 | $68.7M | $32.7M | ||
| Q4 24 | $76.7M | $41.8M | ||
| Q3 24 | $81.0M | $33.3M | ||
| Q2 24 | $93.2M | $29.1M | ||
| Q1 24 | $75.6M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-110.7M | $-52.9M | ||
| Q2 25 | $-29.2M | $-46.6M | ||
| Q1 25 | $-52.9M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $-26.6M | $-43.6M | ||
| Q2 24 | $-34.5M | $-32.3M | ||
| Q1 24 | $-54.4M | $-141.4M |
| Q4 25 | -11.5% | 91.6% | ||
| Q3 25 | 10.3% | 89.3% | ||
| Q2 25 | 11.5% | 88.6% | ||
| Q1 25 | -1.5% | 88.8% | ||
| Q4 24 | 13.1% | 90.9% | ||
| Q3 24 | 17.7% | 88.5% | ||
| Q2 24 | 14.7% | 89.9% | ||
| Q1 24 | 4.9% | 89.2% |
| Q4 25 | -211.4% | -82.2% | ||
| Q3 25 | -160.0% | -102.6% | ||
| Q2 25 | -46.6% | -93.4% | ||
| Q1 25 | -81.8% | -143.7% | ||
| Q4 24 | -49.3% | -98.6% | ||
| Q3 24 | -38.2% | -132.0% | ||
| Q2 24 | -36.4% | -139.2% | ||
| Q1 24 | -70.7% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | -157.6% | -103.1% | ||
| Q2 25 | -39.0% | -96.1% | ||
| Q1 25 | -77.0% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | -32.8% | -131.2% | ||
| Q2 24 | -37.0% | -110.9% | ||
| Q1 24 | -71.9% | -544.4% |
| Q4 25 | $0.68 | $-0.73 | ||
| Q3 25 | $-1.44 | $-0.82 | ||
| Q2 25 | $-0.38 | $-0.75 | ||
| Q1 25 | $-0.69 | $-0.81 | ||
| Q4 24 | $-0.65 | $-0.71 | ||
| Q3 24 | $-0.41 | $-0.73 | ||
| Q2 24 | $-0.53 | $-0.55 | ||
| Q1 24 | $-0.84 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $203.9M | $388.9M |
| Total DebtLower is stronger | $415.7M | — |
| Stockholders' EquityBook value | $-997.0K | $139.1M |
| Total Assets | $614.7M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $203.9M | $388.9M | ||
| Q3 25 | $117.3M | $416.1M | ||
| Q2 25 | $103.5M | $291.0M | ||
| Q1 25 | $102.1M | $314.5M | ||
| Q4 24 | $131.9M | $320.6M | ||
| Q3 24 | $121.7M | $298.4M | ||
| Q2 24 | $144.9M | $319.1M | ||
| Q1 24 | $157.9M | $201.2M |
| Q4 25 | $415.7M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $-997.0K | $139.1M | ||
| Q3 25 | $-784.1M | $148.8M | ||
| Q2 25 | $-677.0M | $-11.9M | ||
| Q1 25 | $-649.5M | $18.9M | ||
| Q4 24 | $-601.2M | $21.7M | ||
| Q3 24 | $-611.9M | $11.2M | ||
| Q2 24 | $-590.0M | $39.3M | ||
| Q1 24 | $-561.4M | $61.6M |
| Q4 25 | $614.7M | $480.2M | ||
| Q3 25 | $599.7M | $506.9M | ||
| Q2 25 | $691.7M | $372.7M | ||
| Q1 25 | $643.8M | $386.7M | ||
| Q4 24 | $678.1M | $392.3M | ||
| Q3 24 | $692.9M | $363.6M | ||
| Q2 24 | $711.2M | $381.8M | ||
| Q1 24 | $735.0M | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-46.8M | $-25.4M |
| Free Cash FlowOCF − Capex | $-49.8M | — |
| FCF MarginFCF / Revenue | -80.8% | — |
| Capex IntensityCapex / Revenue | 4.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-157.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-46.8M | $-25.4M | ||
| Q3 25 | $-38.8M | $-26.6M | ||
| Q2 25 | $-33.2M | $-23.3M | ||
| Q1 25 | $-26.1M | $-40.4M | ||
| Q4 24 | $-29.0M | $-18.8M | ||
| Q3 24 | $-22.0M | $-25.2M | ||
| Q2 24 | $-16.0M | $-29.1M | ||
| Q1 24 | $-31.8M | $-40.7M |
| Q4 25 | $-49.8M | — | ||
| Q3 25 | $-41.7M | — | ||
| Q2 25 | $-35.1M | — | ||
| Q1 25 | $-30.6M | — | ||
| Q4 24 | $-35.4M | — | ||
| Q3 24 | $-24.1M | — | ||
| Q2 24 | $-17.3M | — | ||
| Q1 24 | $-33.0M | — |
| Q4 25 | -80.8% | — | ||
| Q3 25 | -59.4% | — | ||
| Q2 25 | -46.9% | — | ||
| Q1 25 | -44.6% | — | ||
| Q4 24 | -46.2% | — | ||
| Q3 24 | -29.7% | — | ||
| Q2 24 | -18.6% | — | ||
| Q1 24 | -43.7% | — |
| Q4 25 | 4.8% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 6.5% | — | ||
| Q4 24 | 8.4% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.6% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
